CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
tanespimycindrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Histologically or cytologically confirmed relapsed or refractory mantle cell lymphoma, anaplastic large cell lymphoma (CD30-positive disease), or classical Hodgkin's lymphoma
  • ✓1–3 prior treatment regimens for lymphoma (monoclonal antibody therapy, cytokine therapy, or involved field radiotherapy do not count as regimens)
  • ✓Measurable disease: ≥1 unidimensionally measurable lesion ≥20 mm
  • ✓Not a candidate for stem cell transplantation
Key exclusion· 15
  • ✕Prior allogeneic stem cell transplantation
  • ✕Pulmonary lymphoma or known CNS lymphoma
  • ✕LVEF ≤40% by MUGA
  • ✕QTc ≥450 msec in men or ≥470 msec in women

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117988
NCT00117988Phase 2Completed
CompareCT.gov

A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)

National Cancer Institute (NCI)·interventional·Posted Jul 11, 2005·Updated May 30, 2014

In Brief

A Phase 2 clinical trial evaluating tanespimycin for Anaplastic Large Cell Lymphoma and 2 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This phase II trial is studying how well 17-AAG works in treating patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or Hodgkin's lymphoma. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2005
Enrollment StartFeb 1, 2005
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 21.0 years ago

Interventions

tanespimycindrug